HypertensionNCT07055763
Effect Of Nigella Sativa Oil for the Treatment of Hypertension
A study testing Nigella sativa (black seed) in people with Hypertension, run by Superior University at 1 site in Pakistan.
Trial summary
My research explores the antihypertensive effects of Nigella sativa (black seed) oil in managing high blood pressure. Hypertension is a growing global health concern, often insufficiently controlled by standard medications. Read more about this study
- Who is it for?
- Ages 30 to 70 years
- Conditions the study is for
- Hypertension
- What is being tested?
- Nigella sativa (black seed)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 sitePakistan
- Study dates
- 17 Mar 2022to 28 Feb 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 30 to 70 years
- Diagnosed with mild to moderate hypertension (BP ≥140/90 mmHg)
- Willing to participate and provide written informed consent
- Not currently on any herbal or nutritional supplements
Who cannot join
- History of smoking or alcohol consumption
- Pregnant, postmenopausal, or breastfeeding women
- Use of dietary supplements or medications containing antioxidants, caffeine, estrogen, or steroids
- Individuals engaging in regular vigorous physical exercise
- Those adding extra salt to their meals
- Known allergy to Nigella sativa or black seed oil
Trial locations and contacts
1 site in 1 country.
About this study
My research explores the antihypertensive effects of Nigella sativa (black seed) oil in managing high blood pressure. Hypertension is a growing global health concern, often insufficiently controlled by standard medications. Nigella sativa, known for its bioactive compound thymoquinone, possesses antioxidant, anti-inflammatory, and vasodilatory properties, making it a potential natural remedy for blood pressure regulation.
- Conditions
- Hypertension
- Being tested
- Nigella sativa (black seed)
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nigella sativa (black seed)Combination product
Participants in Group 1 (intervention group) will receive Nigella sativa (black seed) oil at a dosage of 0.5 ml, administered orally twice daily-once before breakfast and once before bedtime-for a duration of 12 weeks. The oil, sourced from a standardized local supplier, is rich in thymoquinone, known for its antioxidant and vasodilatory properties. Blood pressure will be measured at baseline and biweekly intervals using a calibrated digital sphygmomanometer to monitor changes in systolic and diastolic values. Participants will also be monitored regularly for any adverse effects.
| Study group | Role | What they receive |
|---|---|---|
| Nigella sativa Oil Supplementation | Experimental | Not described Receives: Combination Product: Nigella sativa (black seed) |
| No Intervention (Control Group) | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Structured Patient History Questionnaire
A pre-designed, structured questionnaire will be used at baseline to collect demographic information, medical history, medication use, dietary habits, and lifestyle factors. This is a qualitative tool without a scoring system but is essential for eligibility confirmation and contextual analysis
Measured: 12 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2025
- Study start17 Mar 2022
- Primary completion1 Sep 2025 (estimated)
- Study completion28 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by Superior UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Superior University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Muhammad Naveed Babur, Superior University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07055763
- Sponsor's protocol ID
- MSAHSW/Batch-Fall23/924
- Status last verified
- Jun 2025
- First submitted
- 28 Jun 2025
- Last updated
- 9 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect Of Nigella Sativa Oil for the Treatment of Hypertension
- ClinicalTrials.gov ID
- NCT07055763
- Acronym / sponsor ID
- MSAHSW/Batch-Fall23/924
- Conditions
- Hypertension
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Superior UniversityUniversity, hospital or other
- Study start
- 17 Mar 2022 (actual)
- Primary completion
- 1 Sep 2025 (estimated)
- Study completion
- 28 Feb 2026 (estimated)
- First posted
- 9 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
My research explores the antihypertensive effects of Nigella sativa (black seed) oil in managing high blood pressure. Hypertension is a growing global health concern, often insufficiently controlled by standard medications. Nigella sativa, known for its bioactive compound thymoquinone, possesses antioxidant, anti-inflammatory, and vasodilatory properties, making it a potential natural remedy for blood pressure regulation.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Nigella sativa Oil Supplementation | Experimental | Combination Product: Nigella sativa (black seed) |
| No Intervention (Control Group) | No intervention | – |
Who may qualify
- Ages
- 30 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults aged 30 to 70 years
- Diagnosed with mild to moderate hypertension (BP ≥140/90 mmHg)
- Willing to participate and provide written informed consent
- Not currently on any herbal or nutritional supplements
Key exclusion criteria (6 listed)
- History of smoking or alcohol consumption
- Pregnant, postmenopausal, or breastfeeding women
- Use of dietary supplements or medications containing antioxidants, caffeine, estrogen, or steroids
- Individuals engaging in regular vigorous physical exercise
- Those adding extra salt to their meals
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nigella sativa (black seed)Participants in Group 1 (intervention group) will receive Nigella sativa (black seed) oil at a dosage of 0.5 ml, administered orally twice daily-once before breakfast and once before bedtime-for a duration of 12 weeks. The oil, sourced from a standardized local supplier, is rich in thymoquinone, known for its antioxidant and vasodilatory properties. Blood pressure will be measured at baseline and biweekly intervals using a calibrated digital sphygmomanometer to monitor changes in systolic and diastolic values. Participants will also be monitored regularly for any adverse effects. | Combination product | Nigella sativa Oil Supplementation |
Primary outcome
Structured Patient History Questionnaire
Time frame: 12 Months
A pre-designed, structured questionnaire will be used at baseline to collect demographic information, medical history, medication use, dietary habits, and lifestyle factors. This is a qualitative tool without a scoring system but is essential for eligibility confirmation and contextual analysis
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nigella sativa (black seed) in people with Hypertension, run by Superior University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 9 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Structured Patient History Questionnaire (time frame: 12 Months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2025.